Is Inozyme Pharma (NASDAQ:INZY) A Risky Investment?
Inozyme Gets Fast Track Status for Candidate for Rare Calcification Condition
H.C. Wainwright Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $14
Buy Rating Affirmed for Inozyme Pharma Amid Promising Drug Developments and Strong Revenue Projections
Express News | Inozyme Pharma Shares Are Trading Higher After the Company Announced That the FDA Granted Fast Track Designation to INZ-701 for the Treatment of ABCC6 Deficiency
Express News | Inozyme Pharma Inc - Targets Pivotal Study for Inz-701 by Year-End
Express News | Inozyme Pharma Announces FDA Fast Track Designation for Inz-701 in Abcc6 Deficiency
Why Did Inozyme Pharma, Inc. (INZY) Get a Strong Buy Rating From Analysts?
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)
Inozyme Pharma Initiated at Overweight by Wells Fargo
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference
Express News | Inozyme Pharma Inc : Wells Fargo Initiates Coverage With Overweight Rating; Target Price $14
Express News | Inozyme Pharma To Present Phase 1/2 Trial Data Of INZ-701 In Adults With ENPP1 Deficiency And ABCC6 Deficiency
Inozyme Pharma to Present Recently Announced Data From Phase 1/2 Trials of INZ-701 in Adults With ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham
Inozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline Prospects
Express News | Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
Inozyme Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)